share_log

我武生物(300357.SZ):目前公司子公司在研的干细胞药物处于临床前研究阶段,无法预计产业化时间

Obu Biology (300357.SZ): Currently, the stem cell drug being developed by the company's subsidiary is in the preclinical research stage, and it is impossible to predict the time of industrialization

Gelonghui Finance ·  May 10 06:41

Gelonghui, May 10 | Our Wu Biology (300357.SZ) said on the investor interactive platform that the indications for stem cell drug research projects can be reviewed in advance. Furthermore, innovative drug development has the characteristics of long cycle, large investment, and high uncertainty. Currently, stem cell drugs being developed by the company's subsidiaries are in the preclinical research stage, and it is impossible to predict the time for industrialization.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment